Transcript Document 7232408
FUNGAL INFECTIONS and ANTIFUNGAL AGENTS
AIMS & OBJECTIVES
• • To provide an overview of the medically important fungal infections • List and classify Antifungal drug classes with their modes of action Make some key learning points through illustrated cases
The Fungal Kingdom
• Diverse groups of eukaryotic organisms that find nourishment from living or dead organic matter • Their classification is based on their structural appearance • During evolution relied on both sexual and asexual reproduction • Both forms important for identification
FUNGI
•
Saccharomyces cerevisiae
is the model organism for studying yeast genetics • Many seen as harmless environmental organisms • Of the 50-250,000 fungal species less than 200 cause human disease and only a dozen or so on a regular basis
Fungi of medical importance: Classification • • • • Based on the colony morphology, vegetative
hyphae
that produce a
mycelium
and specialised aerial hyphae that bear
spores ( conidia ) Yeasts : unicellular fungi reproduce by budding Moulds (filamentous): produce hyphae and mycelium Dimorphic : grow as moulds (environment) or yeasts (in human host)
YEAST:
Blastospore; hyphae; pseudohyphae
MOULD:
Mycelium; hyphae
Some examples
• Yeast :
Candida albicans, Cryptococcus neoformans
• Mould :
Aspergillus, Penicillium, Fusarium, Dermatophytes
• Dimorphic :
Histoplasma capsulatum
Types of diseases caused by human fungal pathogens
•
Mycotoxicosis:
due to ingestion of the toxic metabolites of mould fungi eg, poisonous toadstools
Mycotoxins
•
Aspergillus flavus
• Aflatoxin(hepatic ca) •
A ochraceus
• Ochratoxin (renal tox) • •
Fusarium moniliforme F graminearum
• Fumonisins (oesophageal ca) • Deoxynivalenol (gastrointestinal toxicity)
Allergic lung disease
• Due to inhalation of fungal spores • eg,
A fumigatus
, causing a type I or type III hypersensitivity reaction • A clinical example is called allergic bronchopulmonary aspergillosis • Farmers lung is another example
Fungi of medical importance •
Candida albicans
• Other
Candida
sp.
•
Cryptococcus
• Dermatophytes •
Aspergillus
spp Zygomycetes • Dimorphic fungi • Dematiaceous fungi
Candida albicans
x 6049
Classification of human fungal infections
• Superficial: ringworm (dermatophytes) , thrush (
Candida
(
Pityrosporum
) species), dandruff • Subcutaneous: involve the dermis of the skin, deep tissues or bone. Usually found in tropics/sub-tropics where caught walking barefoot eg, mycetoma • Systemic: due to pathogenic (
Histoplasma
) or opportunistic (
Aspergillus
) fungi
Dermatophytes (the cause of RINGWORM )
• Infection of scalp (Tinea capitis), trunk (Tinea corporis) or nails (Tinea unguium) • Causative fungi are
Trichophyton, Epidermophyton
,
Microsporum
• Geophilic, zoophylic, anthropophylic • Clinically red patches on skin, or scalp, scaly, hair loss • Athletes foot an example
Some other skin fungal infections
• Seborrhoeic dermatitis (
Pitysporum
) • Pityriasis versicolor (
Pitysporum
) • Candidiasis (
Candida albicans)
Vaginal Candidiasis (Thrush) Common in women of child bearing years Symptoms are itchy vaginal discharge Diagnosed by vaginal examination (white plaques) and microscopy/culture Treat: topical pessary Or Fluconazole
SYSTEMIC (DEEP/INVASIVE) FUNGAL INFECTIONS: MAJOR EXAMPLES • Candidiasis • Aspergillosis • Cryptococcosis • Other mould infections • Endemic mycoses • Emerging fungal infections
ILLUSTRATION OF SOME CASES
CANDIDIASIS: CASE 1
• A 70-year old man has colonic surgery for carcinoma of colon • Recovery is in the ITU • He develops high fevers which don’t respond to antibiotics • An organism is grown from blood cultures which is seen on gram stain
Candida blastospores (yeast) In blood
Candidaemia
GERM TUBE
CANDIDIASIS:CASE 1………..
•
Candida albicans
is identified • He is treated with a systemic antifungal drug called amphotericin B intravenously • He develops rigors each time the drug is given and after 7 days treatment although he is improving kidney failure develops and he requires haemofiltration • Treatment is changed to fluconazole
SYSTEMIC (invasive) CANDIDIASIS • Increasing in incidence • Risk factors are prior colonisation of mucosal surfaces, antibiotics, major surgery, leukaemia, vascular catheters • Main pathogenic species is
Candida albicans
(others are
C tropicalis, C glabrata, C krusei
)
Distribution of Nosocomial Bloodstream Pathogens in a Large Teaching Hospital 19.5% 4.5% 26% 4.5% 6% 17% 5.5% Crowe
et al
:
Eur J Clin Microbiol Infect Dis
1998 9% S. aureus CNS Enterococcus Enterobacteriaciae P. aeruginosa Acinetobacter Polymicrobial Fungi N=259
14% Distribution of candidaemia by species ( Hammersmith Hospital 1997-2000) 6% 2% 44% 8% C. albicans C. glabrata C. parapsilosis C. tropicalis C. lusitaniae other mixed N=50 24%
General patterns of susceptibility of
Candida
species
Candida species Fluco Itraco Vorico Flucy AmB Candins
C. albicans C. tropicalis
S S S S S S S S S S S S
C. parapsilosis C. glabrata C. krusei
S S S SDD R SDD R R SDD R S - I S – I S S I R S S – I S – I S (- I?) S S
C. lusitaniae
S S S S S R S Pappas
et al
CID 2004; 38: 161-189
Interpretive breakpoints for isolates of
Candida
species
Drug Fluconazole Itraconazole Flucytosine
Susceptible ≤8
MIC range (
g/ml)
Intermediately susceptible 16-32 (SDD) Resistant >32 ≤0.125
0.25-0.5 (SDD) ≤4 8.16
> 0.5
>16 Pappas
et al
CID 2004; 38: 161-189
Candida biofilms (on vascular catheter): a source of candidaemia Courtesy of Dr J Douglas
Clinical manifestations of candidaemia/invasive candidiasis
• Infective endocarditis (heart valve surgery, IVDAs) • Endophthalmitis • Embolic skin lesions (petechial rash) • Hepatic, renal, cerebral, meningeal infection
ANOTHER CASE……….
• Case no 2: a man who is HIV antibody positive • He complains of difficulty with swallowing and retrosternal burning • Endoscopy reveals white plaques on the oesophageal mucosa typical of Candida (thrush)
FINALLY: SOME LEARNING POINTS ABOUT CANDIDIASIS • In immunocompromised relapses often occur unless underlying problem is removed • Candida endocarditis often requires surgery • Fluconazole resistance has been reported in AIDS cases because of the high fungal load • Disseminated candidiasis is difficult to diagnose
Antifungal Drugs Currently licensed for systemic therapy
• POLYENES: examples: amphotericin B, nystatin: Including 3 lipid formulations of amB (Ambisome) • AZOLES: – Imidazoles: miconazole, ketoconazole – Triazoles: fluconazole, itraconazole, voriconazole • FLUORINATED PYRIMIDINE: • ALLYLAMINE: terbinafine • CANDINS: new antifungal class flucytosine
MEMBRANE FUNCTION
Amphotericin B Nyststin
CELL WALL SYNTHESIS Caspofungin Anidualfungin Micafungin ERGOSTEROL SYNTHESIS
Azoles: Fluconazole, itraconazole, voriconazole
ALLYLAMINE:
Terbinafine
NUCLEIC ACID SYNTHESIS 5-Flucytosine
Targets of action of antifungal drugs
AMPHOTERICIN B vs FLUCONAZOLE • Polyene antifungal • Inhibits cell membrane • Broad spectrum • Not absorbed • Causes rigors • Causes kidney damage • Resistance rare • Azole antifungal • Inhibits cytochrome p450 ( ergosterol) • Broad spectrum • Orally absorbed • Few side effects • No kidney damage • Resistance occurs
Caspofungin
• New class • Fungicidal • Broad spectrum – not
Cryptococcus
• Few side effects • o.d. regimen • No cross resistance with azoles & polyenes
Mechanism of Action
CANDINS Ergosterol
Antifungal drug resistance
• Rare in
Candida albicans
except in AIDS patients • Some fungi are inherently resistant to antifungal: aspergillus and fluconazole • Others acquire resistance following exposure eg,
C albicans
in oropharyngeal infection in an AIDS patient
Azole drug Resistance mechanisms Drug sensitive cell Drug resistant cell mediated by efflux or Mutation in target
ERG11
gene
Acquired Resistance to Fluconazole in HIV associated Oropharyngeal Candidiasis Fluconazole quickly became established as the drug of choice Effective doses have ranged between 50mg and 400mg Since the late 1980’s there have been many reports of clinical failure
ASPERGILLOSIS
• Saprophytic (aspergilloma), allergic (ABPA) and invasive forms of this infection • Environmental fungus
Aspergillus
pathogen • Acquired by inhalation is the • Pulmonary disease is main feature • Difficult to diagnose & high mortality
Conidia Hypha and “fruiting head” Of Aspergillus
Airborne conidia How Aspergillus infection is acquired Alveolar macrophage
ASPERGILLOSIS: CASE STUDY • A 23-year old man suffering from acute myeloid leukaemia undergoes a therapeutic bone marrow transplant • • There follows a long period of neutropenia He complains of pleuritic chest pain, breathlessness and has a fever • Antibiotics make no difference
ASPERGILLOSIS CASE CONT’D
……...
• Chest x ray is performed: infiltrates • This is followed by a CT scan • He also undergoes bronchoscopy which reveals some white plaques • The patient dies despite amphotericin B therapy (there was no recovery of his bone marrow)
Risk groups for Invasive Aspergillosis
• Syndromes/treatments with severe neutropenia • Haematological malignancy • Chronic immunosuppression • Solid organ transplantation • AIDS • Chronic granulomatous disease • Chronic lung diseases: sarcoidosis
Another mould infection: Zygomycosis
• Patients with Haematological malignancy at risk • Diabetic patients also susceptible • Rhinocerebral infection a feature • Eye swelling and cellulitis also seen • Antifungal therapy not effective • Due to several related mould fungi eg,
Rhizopus
ANOTHER SYTEMIC FUNGAL INFECTION: CRYPTOCOCCOSIS • A man who had a kidney transplant is receiving immunosuppression with prednisone and azathioprine • He develops headache over several days, followed be photophobia and neck stiffness • Spinal fluid is obtained which reveals a high count of lymphocytes
CASE CONT’D………..
• A special stain called India ink reveals the presence of round cells surrounded by haloes as illustrated • These haloes are the capsule of the yeast
Cryptococcus neoformans
• A silver stain of a skin biopsy also shows many yeast cells
Cryptococcosis (India ink stain)
CRYPTOCOCCOSIS
• A major opportunistic infection in AIDS • Also occurs in chronically immunosuppressed patients eg, organ transplant • Causes insidious meningitis in spinal fluid with lymphocytes • Treatment is amphotericin B + flucytosine (as in IDSA treatment guidelines)
ENDEMIC MYCOSES
• Histoplasmosis (
H capsulatum, H duboisii)
• Blastomycosis
(B dermatitidis)
• Coccidioidomycosis (
C immitis
) • Paracoccidioidomycosis
HISTOPLASMOSIS
• • • • • Has a specific geographical distribution For example it is endemic in some mid west states in USA Evidence of endemicity is from skin testing of healthy population May cause a self-limiting flu-like illness in immunocompetent Severe pneumonia in immunocompromised
Emerging fungal pathogens
• Increasingly being seen in severely immunocompromised • Susceptibility to antifungals unpredictable • Often these are environmental organisms • Fusarium is reported to be the 4 th most common opportunist fungus in some US centres
SUMMARY POINTS
• • • Superficial fungal infections are a not uncommon presenting complaint in primary care Invasive fungal infections are associated with compromised patients and are seen in hospital practice Limited antifungal therapies make them more difficult to treat than bacterial infection